leukotriene-b4 has been researched along with acetohydroxamic-acid* in 3 studies
1 review(s) available for leukotriene-b4 and acetohydroxamic-acid
Article | Year |
---|---|
The effects of a novel series of selective inhibitors of arachidonate 5-lipoxygenase on anaphylactic and inflammatory responses.
In conclusion, we have described a novel series of acetohydroxamic acids that are potent and selective inhibitors of arachidonate 5-lipoxygenase in vitro and in vivo. In addition, we have shown that these compounds attenuate "leukotriene-dependent" anaphylactic bronchospasm, the accumulation of inflammatory leukocytes, and the development of fever in experimental models. It now remains to be determined if these compounds have any therapeutic value in man. Topics: 5,8,11,14-Eicosatetraynoic Acid; Anaphylaxis; Animals; Arachidonate 5-Lipoxygenase; Arachidonate Lipoxygenases; Arachidonic Acid; Arachidonic Acids; Bronchial Provocation Tests; Bronchial Spasm; Fever; Gastric Mucosa; Guinea Pigs; Humans; Hydroxamic Acids; Inflammation; Leukocytes; Leukotriene B4; Lipoxygenase Inhibitors; Masoprocol; Rats; SRS-A | 1988 |
2 other study(ies) available for leukotriene-b4 and acetohydroxamic-acid
Article | Year |
---|---|
Selective inhibition of arachidonate 5-lipoxygenase by novel acetohydroxamic acids: biochemical assessment in vitro and ex vivo.
1. The chemically novel acetohydroxamic acids, BW A4C, BW A137C and BW A797C, are potent inhibitors of the synthesis of leukotriene B4 (LTB4) from arachidonic acid by human leucocyte homogenates: the concentrations required for 50% inhibition (IC50) were 0.1 microM, 0.8 microM and 0.5 microM respectively. Inhibition was less at higher concentrations of arachidonic acid. 2. These compounds also inhibited the synthesis of [14C]-5-HETE from [14C]-arachidonic acid and the calcium-dependent synthesis of LTB4 from 5-HPETE. This, therefore, suggests that they inhibit 5-lipoxygenase and LTA4 synthase. 3. Concentrations of acetohydroxamic acids required to inhibit metabolism of arachidonic acid by cyclo-oxygenase, 12-lipoxygenase and 15-lipoxygenase were 10 to 100 times higher than those required to inhibit 5-lipoxygenase. 4. The compounds were potent inhibitors of LTB4 synthesis induced by the ionophore, A23187, in human intact leucocytes. This inhibition was reversed by washing the cells. They were also potent, selective inhibitors of LTB4 synthesis induced by A23187 in whole rat blood: binding to rat plasma proteins did not greatly reduce the effectiveness of the compounds. 5. The effects of the acetohydroxamic acids, administered either intravenously or orally to rats, on the synthesis of LTB4, and thromboxane B2 (TXB2) in A23187-stimulated blood ex vivo was studied. The three compounds caused dose-dependent inhibition of the synthesis of LTB4 but not TXB2. Inhibition of LTB4 synthesis persisted for up to 6 h after a single oral dose of 50 mg kg-1. 6. The plasma concentrations of unchanged compound determined by h.p.l.c. correlated with the inhibition of LTB4 synthesis ex vivo. Topics: Animals; Arachidonate 5-Lipoxygenase; Arachidonate Lipoxygenases; Asthma; Blood Platelets; Carrier Proteins; Chromatography, High Pressure Liquid; Humans; Hydroxamic Acids; In Vitro Techniques; Leukocytes; Leukotriene B4; Lipoxygenase Inhibitors; Male; Rats; Thromboxane B2 | 1988 |
Selective inhibition of arachidonate 5-lipoxygenase by novel acetohydroxamic acids: effects on acute inflammatory responses.
1. Two selective inhibitors of arachidonate 5-lipoxygenase, BW A4C and BW A797C, have been studied for their effects on acute inflammatory responses following oral administration to rats and mice. 2. The concentrations of the lipoxygenase product leukotriene B4 (LTB4) in 6 h inflammatory exudates, induced in rats by the subcutaneous implantation of carrageenin-soaked polyester sponges, were reduced dose-dependently by BW A4C (ED50 = 2.6 mg kg-1) or BW A797C (ED50 = 14.3 mg kg-1). 3. BW A4C and BW A797C had little or no effect on prostaglandin E2 (PGE2) concentrations in inflammatory exudates (ED50s greater than 100 mg kg-1). 4. Doses of up to 200 mg kg-1 of either BW A4C or BW A797C had no effect on carrageenin-induced oedema in rat paws. 5. BW A4C and BW A797C had little or no effect on carrageenin-induced hyperalgesia in rats or phenyl-benzoquinone-induced writhing in mice. 6. Yeast-induced pyrexia in rats was reduced by both BW A4C (ED50 = 32 mg kg-1) and BW A797C (ED50 = 23 mg kg-1). 7. The accumulation of leucocytes in sponge exudates was reduced dose-dependently by BW A4C (ED50 = 54 mg kg-1) and BW A797C (ED50 = 16.7 mg kg-1). 8. The selective lipoxygenase inhibitors BW A4C and BW A797C do not suppress inflammatory oedema or pain although they are anti-pyretic and they do inhibit leucocyte migration. There is not, however, a close agreement between these in vivo activities and their potencies as lipoxygenase inhibitors. Topics: 4,5-Dihydro-1-(3-(trifluoromethyl)phenyl)-1H-pyrazol-3-amine; Acute Disease; Animals; Arachidonate Lipoxygenases; Dinoprostone; Female; Hydroxamic Acids; Inflammation; Leukocyte Count; Leukotriene B4; Lipoxygenase Inhibitors; Male; Mice; Mice, Inbred Strains; Prostaglandins E; Pyrazoles; Rats; Rats, Inbred Strains | 1988 |